Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder

Urology

Volumn 60, Issue 6, 2002, Pages 1124-1130

  Bol, Marco G W ^a,b,c,d   Baak, Jan P A ^a,b,c,d   Rep, Simon ^a,b,c,d   Marx, Willem L ^a,b,c,d   Kruse, Arnold Jan ^a,b,c,d   Bos, Siebe D ^a,b,c,d   Kisman, Otto ^a,b,c,d   Voorhorst, Feja J ^a,b,c,d  

^a SIR Hospital   (Norway)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c Location Alkmaar   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER;

ACCURACY; ADULT; AGE; AGED; ARTICLE; BCG VACCINATION; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER STAGING; CARCINOMA IN SITU; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; MITOSIS RATE; MORPHOMETRICS; MULTIPLE CANCER; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; CELL NUCLEUS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; MITOTIC INDEX; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0036900561     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01906-4     Document Type: Article

References (34)

1. Lamm D.L. Long term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am. 19:1992;573-580.
2. Kiemeney L.A., Witjes J.A., Verbeek A.L., et al. The clinical epidemiology of superficial bladder cancer. Br J Cancer. 67:1993;806-812.
3. Pawinski A., Sylvester R., Kurth K.H., et al. A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol. 156:1996;1934-1940.
4. Ooms E.C.M., Kurver P.H.J., Veldhuizen R.W., et al. Morphometric grading of bladder tumors in comparison with histologic grading by pathologists. Hum Pathol. 14:1983;144-150.
5. Baak J.P.A. Manual of Quantitative Pathology in Cancer Diagnosis and Prognosis. 1991;7-18 Springer-Verlag, Berlin.
6. Tosoni I., Wagner U., Sauter G., et al. Clinical significance of inter-observer differences in the staging and grading of superficial bladder cancer. BJU Int. 85:2000;48-53.
7. Hovey R.M., Chu L., Balazs M., et al. Genetic alterations in primary bladder cancers and their metastases. Cancer Res. 58:1998;3555-3560.
8. Slaton J.W., Dinney C.P., Veltri R.W., et al. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol. 158:1997;806-811.
9. Reeder J.E., O'Connell M.J., Yang Z., et al. DNA cytometry and chromosome 9 aberrations by fluorescence in situ hybridization of irrigation specimens from bladder cancer patients. Urology. 51:1998;58-61.
10. Suma Y., Takano Y., Masayuki I., et al. Prognostic significance of Ki67 expression in urothelial cell bladder carcinoma after radical cystectomy. Pathol Res Pract. 193:1997;551-556.
11. Vorreuther R., Hake R., Borchmann P., et al. Expression of immunohistochemical markers (PCNA, Ki67, 486p and p53) on paraffin sections and their relation to the recurrence rate of superficial bladder tumors. Urol Int. 59:1997;88-94.
12. Asakura T., Takano Y., Iki M., et al. Prognostic value of Ki67 for recurrence and progression of superficial bladder cancer. J Urol. 158:1997;385-388.
13. Lipponen P.K., Eskelinen M.J. Volume-corrected mitotic index and mitotic activity index in transitional cell bladder cancer. Eur Urol. 18:1991;258-262.
14. Blomjous C.E.M., Vos W., Schipper N.W., et al. The prognostic significance of selective nuclear morphometry in urinary bladder carcinoma. Hum Pathol. 21:1990;409-413.
15. Fontana D., Bellina M., Gubetta L., et al. Monoclonal antibody Ki67 in the study of the proliferative activity of bladder carcinoma. J Urol. 148:1992;1149-1151.
16. Pfister C., Moore L., Allard P., et al. Predictive value of cell cycle markers p53, mdm2, p21 and Ki67 in superficial bladder tumor recurrence. Clin Cancer Res. 5:1999;4079-4084.
17. Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma a marker for disease progression . J Natl Cancer Inst. 85:1993;53-59.
18. Raitanen M.P., Tammela T.L., Kallioinen M., et al. p53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J Urol. 157:1997;1250-1253.
19. Sidransky D., Von Eschenbach A., Tsai Y.C., et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 252:1991;706-709.
20. Popov Z., Hoznek A., Colombel M., et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer. 80:1997;1472-1481.
21. Mostofi F.K., Sobin L.H., Torloni H. WHO Histologic Typing of Urinary Bladder Tumors. 1973;15-34 Springer, Berlin.
22. Dalesio O., Schulman C.C., Sylvester R., et al. Prognostic factors in superficial bladder tumors a study of the European Organization for Research on Treatment of Cancer . Urology. 29:1983;730-733.
23. Smits G., Schaafsma E., Kiemeney L., et al. Microstaging of pT1 transitional cell carcinoma of the bladder identification of subgroups with distinct risks of progression . Urology. 52:1998;1009-1013.
24. A,1 transitional cell carcinomas of the urinary bladder by quantitative nuclear and proliferation related features. J Clin Pathol. 54:2001;854-859.
25. Oosterhuis J.W., Schapers R.F., Janssen-Heijnen M.L., et al. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder clinical significance and comparison with other prognostic factors . Cancer. 88:2000;2598-2605.
26. Schapers R.F., Pauwels R.P., Wijnen J.T., et al. A simplified grading method of transitional cell carcinoma of the urinary bladder reproducibility, clinical significance and comparison with other prognostic variables . Br J Urol. 73:1994;625-631.
27. Fleege J.C., Baak J.P., Smeulders A.W. Analysis of measuring system parameters that influence reproducibility of morphometric assessments with a graphic tablet. Hum Pathol. 19:1988;513-517.
28. Jannink I., Bennen J.N., Blaauw J., et al. At convenience and systematic random sampling effects on the prognostic value of nuclear area assessments in breast cancer patients . Breast Cancer Res Treat. 36:1995;55-60.
29. Ooms E.C.M., Anderson W.A.D., Alons C.L., et al. Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol. 14:1989;140-144.
30. Prives C., Hall P.A. The p53 pathway. J Pathol. 187:1999;112-126.
31. Esrig D., Spruck C.H. III, Nichols P.W., et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 143:1993;1389-1397.
32. McShane L.M., Aamodt R., Cordon-Cardo C., et al. Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res. 6:2000;1854-1864.
33. Nakopoulou L., Vourlakou C., Zervas A., et al. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol. 29:1998;146-154.
34. Kruger S., Muller H. Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol. 75:1995;480-484.